For research use only. Not for therapeutic Use.
rel-VU6021625 (Cat No.: I040125) is a selective small-molecule inhibitor designed to target specific pathways involved in neurodegenerative diseases, particularly in relation to protein misfolding and aggregation. It has been studied for its potential to modulate protein interactions and reduce neuroinflammation, making it a promising candidate for treating conditions such as Alzheimer’s disease or Parkinson’s disease. By interacting with certain receptors or enzymes, rel-VU6021625 may help protect neurons from damage and prevent disease progression, offering a novel therapeutic approach in neurodegeneration research.
| CAS Number | 2307718-96-1 |
| Synonyms | (3aR,6aS)-N-[6-(2-methylindazol-5-yl)pyridazin-3-yl]-2-(oxan-4-ylmethyl)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-amine |
| Molecular Formula | C25H32N6O |
| Purity | ≥95% |
| InChI | InChI=1S/C25H32N6O/c1-30-14-21-10-18(2-3-24(21)29-30)23-4-5-25(28-27-23)26-22-11-19-15-31(16-20(19)12-22)13-17-6-8-32-9-7-17/h2-5,10,14,17,19-20,22H,6-9,11-13,15-16H2,1H3,(H,26,28)/t19-,20+,22? |
| InChIKey | YGZMGSNKRRWPDT-RLAPIPATSA-N |
| SMILES | CN1C=C2C=C(C=CC2=N1)C3=NN=C(C=C3)NC4CC5CN(CC5C4)CC6CCOCC6 |
| Reference | [1]. Moehle MS, et al. Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy. ACS Pharmacol Transl Sci. 2021 Aug 2;4(4):1306-1321. |
